跳轉至內容
Merck
全部照片(1)

文件

ABK0006

Sigma-Aldrich

SynaBridge ELISA试剂盒

登入查看組織和合約定價


About This Item

分類程式碼代碼:
41116158
NACRES:
NA.32

抗體表格

IgG fraction of antiserum

物種活性

human (Human IgG)

運輸包裝

wet ice

儲存溫度

2-8°C

一般說明

A Protein Conformational Array (PCA) in a sandwich ELISA format where the plate is coated with a panel of antibodies raised against peptides derived from the full length protein sequence of Palivizumab. Taken individually, each of these antibodies is strongly antigenic to the peptide sequence that was used in its production. However, when these peptides are incorporated into a full length correctly folded protein, the antigenicity of many of them is masked by the three dimensional structure of the protein and only a limited number of the antibodies respond. The result is a histogram which can be likened to a ‘fingerprint′ for correctly folded Palivizumab. For a Synagis Biosimilar, if the protein is correctly folded and glycosylated, the ‘fingerprint′ will match that of Palivizumab. If it is not correctly folded, previously masked peptide sequences will be exposed and will be recognized by the antibody made to that exposed sequence. In this way, changes in the ‘fingerprint′ generated by the ELISA will point out differences between the Biosimilar and authentic Palivizumab.

應用

For research use only. Not for use in diagnostic procedures.

象形圖

Corrosion

訊號詞

Warning

危險聲明

危險分類

Eye Irrit. 2 - Met. Corr. 1 - Skin Irrit. 2

儲存類別代碼

8A - Combustible corrosive hazardous materials

水污染物質分類(WGK)

WGK 1


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Xing Wang et al.
Frontiers in pharmacology, 4, 103-103 (2013-08-24)
Antibody arrays were developed to probe a monoclonal antibody's three-dimensional structure (3-D structure). Peptides with overlapping regions were designed to cover the whole mAb light chain and heavy chain, respectively, and used to generate polyclonal antibodies after the conjugation of
Yuanli Song et al.
mAbs, 10(3), 397-405 (2018-01-10)
The elucidation of antibody higher order structure (HOS) is critical in therapeutic antibody development. Since HOS determines the protein bioactivity and chemo-physical properties, this knowledge can help to ensure that the safety and efficacy attributes are not compromised. Protein conformational
Biosimilar mAb in-process Sample Higher Order Structure Analysis with Protein Conformational Array ELISA.
Michael Davies, Gan Wang, Jian Gong, Guofeng Fu and Xing Wang
Pharmaceut. Res., 1-11 (2016)
Soon Kwan Jung et al.
mAbs, 6(5), 1163-1177 (2014-12-18)
Remsima (infliximab) was recently approved as the world's first biosimilar monoclonal antibody (mAb) in both the European Union and Korea. To achieve this, extensive physicochemical characterization of Remsima in relation to Remicade was conducted in order to demonstrate the highly

文章

Monoclonal antibodies (mAbs) lead biologics growth, predicted $125 billion worldwide sales by 2020, emphasizing their therapeutic significance.

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務